Quasar Medical has completed its acquisition of Nordson Corporation’s design and development contract manufacturing businesses in Galway, Ireland; and Tecate, Mexico. The company did not disclose the deal’s financial terms.

The acquisition fosters Quasar’s evolution into a fully integrated contract development and manufacturing organization (CDMO), offering customers concept-to-commercialization solutions worldwide. The company is expanding its workforce by nearly 200 employees, including expert development engineers and technicians, creating new opportunities for advancement.

“This strategic acquisition marks an exciting new chapter for Quasar and the customers we serve,” Quasar Medical CEO Alex Wallstein said. “By combining our manufacturing excellence with the design, development, and assembly expertise of the Galway and Tecate teams, we are expanding our global reach, moving closer to our customers, and creating a truly global CDMO platform. Together, we will partner with customers and suppliers earlier in the product lifecycle, delivering innovation, scalability, and speed to market at every stage.”

With this acquisition, Quasar strengthens its global presence with two U.S. Food and Drug Administration-registered, ISO 13485-certified facilities situated in key medtech regions—Europe and North America—improving customer proximity and access. Galway, Ireland, now serves as an innovation hub for design and development services for extrusions, braiding, balloons, and complex catheters, providing advanced support in product design, prototyping, and clinical innovation. Tecate, Mexico, meanwhile, adds cost-effective, high-volume manufacturing capabilities, facilitating a smoother transition from development to commercialization.

 “This is a pivotal milestone that positions Quasar as a strategic partner to our customers—not just a manufacturer,” Quasar Medical Chief Operating Officer Aviel Bohnik stated. “With the addition of Galway and Tecate, we now offer a truly differentiated platform that combines upstream innovation, downstream scalability, and our ramp-up capabilities—accelerating time to market for our customers. These new sites strengthen our ability to deliver high-value solutions through vertical integration, customer collaboration, and operational excellence across key regions.”

By expanding its regional reach and integrating Nordson Medical’s design, development, and contract manufacturing capabilities into its global platform, Quasar can now provide a seamless, end-to-end solution for complex interventional devices, including:

• Advanced product development and rapid prototyping in Galway
• Design-for-manufacturing expertise, balloon catheter and shaft development, and comprehensive testing capabilities
• Scalable manufacturing and assembly in Tecate, including molding, coating, packaging, and automated processes

The acquisition also greatly expands Quasar’s cleanroom footprint, enhances deep technical expertise in extrusions, balloons, balloon catheters, braided shafts, and delivery systems, and creates more room for growth at both sites. Customers will benefit from regional access in North America and Europe, faster development, enhanced quality control, and more cost-effective manufacturing, according to Quasar.

Quasar is collaborating closely with Nordson to ensure a seamless transition for employees, customers, and suppliers.

Quasar Medical is a global CDMO delivering end-to-end solutions for interventional and minimally invasive medical devices. With 11 global facilities and more than 4,200 employees across Asia, North America, and Europe, Quasar specializes in catheter systems, balloon technologies, micro-EM sensors, and complex assemblies, delivering cost-effective scalability and speed to market. Headquartered in Singapore, the company provides fully integrated device solutions spanning design, prototyping, and scalable manufacturing. Quasar operates under ISO 13485:2016 and cGMP standards, serving medical device OEMs and innovators worldwide.